126IN - Lung Cancer Asia Study Group: East

Date 27 September 2014
Event ESMO 2014
Session ESMO-CSCO: Global collaboration in phase I cancer drug development
Topics Drug Development
Bioethics, Legal, and Economic Issues
Presenter Yi-Long Wu
Citation Annals of Oncology (2014) 25 (suppl_4): iv43-iv44. 10.1093/annonc/mdu318
Authors Y. Wu
  • Guangdong Lung Cancer Institute, Guangdong General Hospital, 510080 - Guangzhou/CN




In 2007 a national collaborative clinical research group, Chinese Thoracic Oncology Group (CTONG) was established. There are top 25 hospital members in the group. These hospital members work toward the common goal of controlling, effectively treating and ultimately curing cancer. Research results are provided to world-wide medical communities through scientific publications and academy meeting. Based CTONG trials some significant advances in clinical trials concentrating on high qualities translational research have been rapidly developed in China. Currently CTONG has more than 25 active ongoing clinical trials. They focus on biomarker-driven studies. On early stage NSCLC CTONG initiated neo-adjuvant and adjuvant target therapy for resectable NSCLC based EGFR mutation. On advanced stage there is a head to head to comparing gefitinib with erlotinib trial. CTONG will develop one trial named Cluster trial. This trial will screen patients through snapshot technique for rare mutations and then assign the patients with special mutation to match target therapy. For these biomarker-driven clinical trials they need to screen much more patients than trials with all comer. More than 10000 new lung cancer patients are diagnosed in CONG hospitals per year. Thus biomarker-driven studies could be rapidly initiated in China.

Biomarker-driven clinical trials by CTONG
Trial Number NCT Number Trial status
CTONG 0901 NCT 01024413 Erlotinib versus Gefitinib in advanced NSCLC with EGFR mutation ongoing
CTONG 1103 NCT 01407822 Erlotnib versus Chemo as ne-adjuant in N2 operable NSCLC (EMERGING) Ongoing
CTONG 1104 NCT 01405079 Gefitinib versus Chemo as adjuvnt treatment in N1-2 NSCLC (ADJUVANT) Closed
CTONG 1201 NCT 01724801 Icotinib versus WBI in Brain M NSCLC with EGFR mutation (BRAIN) Ongoing


The author has declared no conflicts of interest.